revenue growth

Vertex Pharmaceuticals eyes 25% stock upside to $600 as it expands beyond cystic fibrosis with new drug approvals and kidney disease candidate povetacicept.

MIG Capital trims $37.4M Sotera Health stake while maintaining significant position. Company posts record profits, 20-year revenue growth streak amid 18% annual share price gain.

Veeva Systems delivered 13.6% CAGR returns since 2013 IPO. Strong competitive advantages and $20B addressable market could support multimillion-dollar returns, but growth is slowing amid increasing competition.

Nvidia invests $2 billion in Nebius, backing AI data center expansion with access to next-gen chips. Revenue expected to surge 531% to $3.35B in 2026.

JPMorgan reiterates Overweight on $ZG, citing durable software and data advantages. Zillow plans $1.25B buyback, projects 15% revenue growth in 2026.

Nebius Group surged 333% annually with Wall Street projecting 36-58% further gains. The neocloud AI data center operator plans massive capacity expansion amid soaring infrastructure demand.

Investment firm 13D Management purchased 52,000 $WK shares worth $4.49M, signaling bullish sentiment despite year-long stock decline amid AI concerns.

$ANGX fell 11.2% after beating revenue targets but missing earnings expectations. Despite 254% YoY revenue growth, losses doubled.

TSMC stock surged 107% in one year, driven by 36% projected 2025 revenue growth and 90% market share in advanced AI chips. At 24.7x forward earnings, analysts view it as a reasonable long-term buy despite its $1.8T valuation.

Recon Technology reports 102% revenue growth to $12.2M in H1 FY2026, driven by international projects and domestic recovery. Net losses narrow significantly.

Syndax Pharmaceuticals attracted $6.54M institutional investment as its approved cancer therapies generated $172.4M revenue, up 629% year-over-year, driving 80%+ stock surge.

Palantir delivers 70% revenue growth with rule of 40 score of 127%, signaling potential bargain despite elevated valuation.

Viant Technology stock surged 12% after posting strong Q4 earnings with 22% revenue growth to $110M and 37% non-GAAP net income growth, beating estimates significantly.

Cancer diagnostics firm $PRPO reports $24M in 2025 revenues, up 30% year-over-year, and publishes peer-reviewed study on its BCR::ABL1 blood test.

Fiverr reports $430.9M revenue (+10.1% YoY) and 21.3% EBITDA margin in 2025 annual filing, demonstrating improved profitability amid competitive pressures.

SoundHound AI stock down 66% despite nearly doubling revenue to $169M. Company guides 33-50% 2026 growth but remains unprofitable with contingent liabilities.

UTI director sells 33% stake near 52-week high. Company shows 14% growth, but elevated P/E suggests pullback ahead.

Bausch + Lomb posted $5.1B in annual revenue with 6% growth as Caspian Capital builds major stake, signaling institutional confidence.

Ballard Power Systems ($BLDP) stock jumped 16.85% after beating Q4 estimates with 70% heavy-duty mobility revenue growth and nearly 800 engine deliveries.

$SAGT acquires 60% of Malaysian restaurant chain Malaya Heritage for $3M, targeting 70% revenue growth in 2026 through technology integration.